Eledon Pharmaceuticals Inc
ELDN1.600USD
+0.030+1.91%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
95.81MMarket Cap
5.87P/E TTM
More Details of Eledon Pharmaceuticals Inc Company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Eledon Pharmaceuticals Inc Info
Ticker SymbolELDN
Company nameEledon Pharmaceuticals Inc
IPO dateSep 17, 2014
CEOGros (David-Alexandre C)
Number of employees31
Security typeOrdinary Share
Fiscal year-endSep 17
Address19800 Macarthur Blvd.
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92612
Phone19492388090
Websitehttps://eledon.com/
Ticker SymbolELDN
IPO dateSep 17, 2014
CEOGros (David-Alexandre C)
Company Executives of Eledon Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. Steven N. Perrin, Ph.D.
Dr. Steven N. Perrin, Ph.D.
President, Chief Scientific Officer, Director
President, Chief Scientific Officer, Director
--
--
Mr. John S. McBride
Mr. John S. McBride
Independent Director
Independent Director
--
--
Mr. Paul Little
Mr. Paul Little
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. David-Alexandre C. (DA) Gros, M.D.
Dr. David-Alexandre C. (DA) Gros, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
9.00K
--
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
677.00
--
Dr. Allan D. Kirk, M.D., Ph.D.
Dr. Allan D. Kirk, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Bryan E. Smith, J.D.
Mr. Bryan E. Smith, J.D.
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. James Robinson
Mr. James Robinson
Independent Director
Independent Director
--
--
Dr. Jan Hillson, M.D.
Dr. Jan Hillson, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Nov 26
Updated: Wed, Nov 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
8.39%
Coastlands Capital LP
6.35%
RA Capital Management, LP
4.75%
The Vanguard Group, Inc.
4.36%
BlackRock Institutional Trust Company, N.A.
4.18%
Other
71.98%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
8.39%
Coastlands Capital LP
6.35%
RA Capital Management, LP
4.75%
The Vanguard Group, Inc.
4.36%
BlackRock Institutional Trust Company, N.A.
4.18%
Other
71.98%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.99%
Investment Advisor
16.91%
Investment Advisor/Hedge Fund
8.26%
Venture Capital
6.18%
Corporation
1.09%
Research Firm
0.61%
Bank and Trust
0.09%
Individual Investor
0.03%
Private Equity
0.02%
Other
44.83%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
174
40.57M
62.44%
+4.76M
2025Q3
174
35.81M
78.25%
-4.68M
2025Q2
155
40.45M
72.00%
+2.71M
2025Q1
116
37.67M
69.38%
-3.87M
2024Q4
99
37.64M
45.44%
+12.04M
2024Q3
63
18.54M
49.04%
+220.67K
2024Q2
64
18.69M
36.55%
+6.56M
2024Q1
59
10.03M
46.51%
-1.52M
2023Q4
57
9.58M
48.06%
+248.88K
2023Q3
59
9.34M
57.16%
-456.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
6.29M
10.51%
--
--
Jun 30, 2025
RA Capital Management, LP
3.57M
5.96%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.32M
5.54%
+365.26K
+12.37%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.92M
4.88%
+2.34M
+406.69%
Jun 30, 2025
Invus Public Equities Advisors, LLC
690.17K
1.15%
--
--
Jun 30, 2025
Zimmer Partners, LP
980.68K
1.64%
+225.71K
+29.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.38M
2.31%
+717.22K
+107.58%
Jun 30, 2025
Sphera Funds Management Ltd.
1.96M
3.27%
-347.51K
-15.06%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.05%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
ALPS Medical Breakthroughs ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.05%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Date
Type
Ratio
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
Oct 02, 2020
Merger
18→1
FAQs
Who are the top five shareholders of Eledon Pharmaceuticals Inc?
The top five shareholders of Eledon Pharmaceuticals Inc are:
BVF Partners L.P. holds 6.29M shares, accounting for 10.51% of the total shares.
RA Capital Management, LP holds 3.57M shares, accounting for 5.96% of the total shares.
The Vanguard Group, Inc. holds 3.32M shares, accounting for 5.54% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.92M shares, accounting for 4.88% of the total shares.
Invus Public Equities Advisors, LLC holds 690.17K shares, accounting for 1.15% of the total shares.
BVF Partners L.P. holds 6.29M shares, accounting for 10.51% of the total shares.
RA Capital Management, LP holds 3.57M shares, accounting for 5.96% of the total shares.
The Vanguard Group, Inc. holds 3.32M shares, accounting for 5.54% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.92M shares, accounting for 4.88% of the total shares.
Invus Public Equities Advisors, LLC holds 690.17K shares, accounting for 1.15% of the total shares.
What are the top three shareholder types of Eledon Pharmaceuticals Inc?
The top three shareholder types of Eledon Pharmaceuticals Inc are:
BVF Partners L.P.
Coastlands Capital LP
RA Capital Management, LP
BVF Partners L.P.
Coastlands Capital LP
RA Capital Management, LP
How many institutions hold shares of Eledon Pharmaceuticals Inc (ELDN)?
As of 2025Q4, 174 institutions hold shares of Eledon Pharmaceuticals Inc, with a combined market value of approximately 40.57M, accounting for 62.44% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -15.81%.
What is the biggest source of revenue for Eledon Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Eledon Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
